 | |||||||||
TeaRx™ is the first diagnostic solution to provide a comprehensive assessment of Dry Eye Syndrome, which potentially reduces empirical treatment practices and undesired costs to the healthcare system
Vancouver, British Columbia – TheNewswire - February 19, 2025 – DiagnosTear Technologies Inc. (CSE: DTR) ("DiagnosTear" or the "Company"), a leader in developing innovative point-of-care diagnostic solutions for eye diseases, is pleased to announce that an abstract titled “A Novel Multi-Parameter Point-of-Care Tear Film Test for Diagnosis of Dry Eye Syndrome, Severe Meibomian Gland Dysfunction, and Responsiveness to Therapy” has been accepted for oral presentation at the prestigious Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held in Salt Lake City, Utah from May 4-8, 2025. The ARVO Annual Meeting is a premier gathering focused on ophthalmology and affiliated fields which will be attended by eye and vision scientists globally.
The abstract, submitted by Prof. Sayan Basu from the Brien Holden Eye Research Center, LV Prasad Eye Institute, Hyderabad, India, the principal investigator of the study, details the results of a large-scale clinical trial conducted at LV Prasad Eye Institute (LVPEI). This trial tested the performance of DiagnosTear's TeaRx™ Dry Eye product, which aims to revolutionize the diagnosis and analysis of Dry Eye Syndrome (DES) by quantifying five protein biomarkers in tear fluid.
To the best of DiagnosTear’s knowledge, this study involved the largest and most diverse cohort of subjects ever studied for DES diagnostics. The study included approximately 500 DES patients and 100 healthy controls, with the following significant findings:
1. TeaRx™ effectively distinguished between severe DES (Grades 3-4) and non-severe DES patients and healthy controls, achieving sensitivity, specificity, and accuracy of 80.6%, 66.7%, and 68%, respectively.
2. The test also differentiated between DES patients of all severity levels (Grades 1-4) and healthy controls, with sensitivity, specificity, and accuracy levels of 72%, 63%, and 70.1%, respectively.
3. TeaRx™ identified the presence of severe Meibomian Gland Dysfunction (MGD), the most common cause of evaporative DES, with sensitivity, specificity, and accuracy of 80.6%, 61.3%, and 76%, respectively.
4. Notably, when used to predict therapeutic responses to Cyclosporin A (CysA) therapy in DES patients, TeaRx™ achieved outstanding results, including a sensitivity of 94%, specificity of 63%, and accuracy of 77%. The product demonstrated a high negative predictive value (NPV) of 92.3%, which can aid in identifying patients unlikely to respond to therapy, thereby improving patient selection for treatment.
Dr. Shimon Gross, CEO of DiagnosTear Technologies, expressed excitement about the study’s acceptance at ARVO, stating: “We are thrilled that these groundbreaking results will be shared at the ARVO Annual Meeting. This study demonstrates that TeaRx™, a non-invasive, multi-parametric test, has excellent diagnostic performance for DES, its severity, and the presence of severe MGD. Additionally, it shows great promise in predicting the effectiveness of topical Cyclosporin A therapy. We believe this opens doors to further research into predicting treatment outcomes for other therapies targeting DES, paving the way for better patient management.”
About DiagnosTear Technologies
DiagnosTear Technologies is a global leader in the development and commercialization of rapid, point-of-care, multi-parametric diagnostic tests for ocular diseases. By leveraging the analysis of tear fluid composition, the company provides innovative diagnostic solutions for conditions like Dry Eye and Red Eye. DiagnosTear is committed to improving patient outcomes and transforming ophthalmic care through cutting-edge diagnostic technologies.
For more information, please contact:
Dr. Shimon Gross
Chief Executive Officer
DiagnosTear Technologies Inc.
Email: shimon@diagnostear.com
DiagnosTear Investor Relations
Email: ir@diagnostear.com
Copyright (c) 2025 TheNewswire - All rights reserved.
